Cyclic Derivatives Modulate MCP-1 Receptor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory, autoimmune, and allergic diseases such as asthma, rheumatoid arthritis, and atherosclerosis are limited in effectively targeting the MCP-1/CCR2 interaction, which plays a crucial role in disease pathogenesis, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of novel cyclic derivatives that act as antagonists or partial agonists/antagonists of MCP-1 receptor activity, administered in pharmaceutical compositions to modulate chemokine activity and reduce inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for inflammatory diseases, then general anti-inflammatory effects are achieved, but specific targeting of MCP-1/CCR2 interaction is insufficient leading to suboptimal therapeutic outcomes
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of cyclic amine compounds to optimize their binding affinity and selectivity for the CCR2 receptor. Through systematic variation of molecular parameters (substituents, ring size, stereochemistry), the compounds achieve enhanced therapeutic effectiveness with specific targeting of the MCP-1/CCR2 interaction, resolving the contradiction between general effectiveness and specific targeting.
2Reliability
If novel cyclic derivatives are developed to specifically target MCP-1/CCR2 interaction, then therapeutic effectiveness is improved, but complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a cyclic amine core structure and variable substituent groups (R1-R6). This modular approach allows optimization of therapeutic effectiveness through specific substituent combinations while maintaining a manageable core structure, thus reducing the overall complexity burden despite enhanced targeting capability.
Solution Approach 2:
The patent applies universality by designing a core cyclic amine structure that can serve multiple therapeutic purposes across different inflammatory conditions (asthma, rheumatoid arthritis, atherosclerosis). The standardized core with variable substituents provides a universal platform that achieves specific CCR2 targeting while avoiding the need to develop entirely new complex structures for each application.
3Object-affected harmful factors
If cyclic amine compounds are used as CCR2 antagonists, then inflammatory responses are reduced, but potential off-target effects on other chemokine receptors may occur
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the molecular structure (local substituents R1-R6 on the cyclic amine core) to enhance binding selectivity for CCR2 while minimizing interactions with other chemokine receptors. This localized optimization of binding properties reduces off-target effects while maintaining effective anti-inflammatory activity through specific CCR2 antagonism.
Data Source
AI summary
The present application describes modulators of MCP-1 of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ transplantation, and cancer.